Advertisement

Ads Placeholder
Loading...

Valbiotis SA

ALVAL.PAEURONEXT
Healthcare
Biotechnology
1.07
-0.02(-2.01%)
U.S. Market opens in 56h 5m

Valbiotis SA Fundamental Analysis

Valbiotis SA (ALVAL.PA) shows weak financial fundamentals with a PE ratio of -2.69, profit margin of -10.41%, and ROE of -1.09%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position34.22%
PEG Ratio-0.09
Current Ratio2.85

Areas of Concern

ROE-1.09%
Operating Margin-10.49%
We analyze ALVAL.PA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1083.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1083.7/100

We analyze ALVAL.PA's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALVAL.PA struggles to generate sufficient returns from assets.

ROA > 10%
-65.45%

Valuation Score

Excellent

ALVAL.PA trades at attractive valuation levels.

PE < 25
-2.69
PEG Ratio < 2
-0.09

Growth Score

Weak

ALVAL.PA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

ALVAL.PA maintains a strong and stable balance sheet.

Debt/Equity < 1
0.73
Current Ratio > 1
2.85

Profitability Score

Weak

ALVAL.PA struggles to sustain strong margins.

ROE > 15%
-108.68%
Net Margin ≥ 15%
-10.41%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALVAL.PA Expensive or Cheap?

P/E Ratio

ALVAL.PA trades at -2.69 times earnings. This suggests potential undervaluation.

-2.69

PEG Ratio

When adjusting for growth, ALVAL.PA's PEG of -0.09 indicates potential undervaluation.

-0.09

Price to Book

The market values Valbiotis SA at 3.64 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.64

EV/EBITDA

Enterprise value stands at -3.06 times EBITDA. This is generally considered low.

-3.06

How Well Does ALVAL.PA Make Money?

Net Profit Margin

For every $100 in sales, Valbiotis SA keeps $-10.41 as profit after all expenses.

-10.41%

Operating Margin

Core operations generate -10.49 in profit for every $100 in revenue, before interest and taxes.

-10.49%

ROE

Management delivers $-1.09 in profit for every $100 of shareholder equity.

-1.09%

ROA

Valbiotis SA generates $-65.45 in profit for every $100 in assets, demonstrating efficient asset deployment.

-65.45%

Following the Money - Real Cash Generation

Operating Cash Flow

Valbiotis SA generates limited operating cash flow of $-8.03M, signaling weaker underlying cash strength.

$-8.03M

Free Cash Flow

Valbiotis SA generates weak or negative free cash flow of $-8.18M, restricting financial flexibility.

$-8.18M

FCF Per Share

Each share generates $-0.35 in free cash annually.

$-0.35

FCF Yield

ALVAL.PA converts -32.35% of its market value into free cash.

-32.35%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.69

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.09

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.64

vs 25 benchmark

P/S Ratio

Price to sales ratio

27.97

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.73

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.85

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.09

vs 25 benchmark

ROA

Return on assets percentage

-0.65

vs 25 benchmark

ROCE

Return on capital employed

-0.93

vs 25 benchmark

How ALVAL.PA Stacks Against Its Sector Peers

MetricALVAL.PA ValueSector AveragePerformance
P/E Ratio-2.6928.45 Better (Cheaper)
ROE-108.68%763.00% Weak
Net Margin-1040.55%-45265.00% (disorted) Weak
Debt/Equity0.730.34 Weak (High Leverage)
Current Ratio2.852795.60 Strong Liquidity
ROA-65.45%-16588.00% (disorted) Weak

ALVAL.PA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Valbiotis SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ